Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ASHISH KAMAT and NEEMA NAVAI.
ASHISH KAMAT
Connection Strength
7.606
NEEMA NAVAI
  1. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gu?rin Have an Effect? Eur Urol. 2024 Oct; 86(4):366-368.
    View in: PubMed
    Score: 0.243
  2. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024 Jun; 133(6):733-741.
    View in: PubMed
    Score: 0.238
  3. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
    View in: PubMed
    Score: 0.233
  4. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023 12; 6(6):590-596.
    View in: PubMed
    Score: 0.229
  5. Bacillus Calmette-Gu?rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023 10; 132(4):384-386.
    View in: PubMed
    Score: 0.227
  6. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol. 2023 08; 210(2):254-255.
    View in: PubMed
    Score: 0.226
  7. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci. 2023 Jul; 53:16-22.
    View in: PubMed
    Score: 0.225
  8. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17.
    View in: PubMed
    Score: 0.218
  9. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2023 01; 209(1):140-149.
    View in: PubMed
    Score: 0.216
  10. Reply by Authors. J Urol. 2022 08; 208(2):290-291.
    View in: PubMed
    Score: 0.212
  11. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Gu?rin Response in High-Grade Ta Tumors. J Urol. 2022 08; 208(2):284-291.
    View in: PubMed
    Score: 0.212
  12. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin. Eur Urol Oncol. 2022 02; 5(1):84-91.
    View in: PubMed
    Score: 0.204
  13. Reduced-dose bacillus Calmette-Gu?rin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. BJU Int. 2022 09; 130(3):323-330.
    View in: PubMed
    Score: 0.204
  14. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Gu?rin? BJU Int. 2022 10; 130(4):463-469.
    View in: PubMed
    Score: 0.204
  15. Reply by Authors. J Urol. 2021 11; 206(5):1267.
    View in: PubMed
    Score: 0.199
  16. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.198
  17. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. 2021 11; 157:181-187.
    View in: PubMed
    Score: 0.198
  18. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World J Urol. 2021 Nov; 39(11):4143-4149.
    View in: PubMed
    Score: 0.197
  19. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer. 2021 May 25; 7(2):243-252.
    View in: PubMed
    Score: 0.197
  20. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Gu?rin Therapy Outcomes. Eur Urol Oncol. 2022 06; 5(3):347-356.
    View in: PubMed
    Score: 0.196
  21. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol. 2021 Sep; 206(3):577-585.
    View in: PubMed
    Score: 0.195
  22. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 08; 35(8):1168-1176.
    View in: PubMed
    Score: 0.195
  23. Reply by Authors. J Urol. 2021 06; 205(6):1620-1621.
    View in: PubMed
    Score: 0.194
  24. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.193
  25. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Gu?rin: Implications for Clinical Trial Design. J Urol. 2021 06; 205(6):1612-1621.
    View in: PubMed
    Score: 0.192
  26. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 04; 39(4):237.e1-237.e5.
    View in: PubMed
    Score: 0.190
  27. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.
    View in: PubMed
    Score: 0.190
  28. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. 2020 10; 17(10):1995-2004.
    View in: PubMed
    Score: 0.185
  29. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 04; 38(4):247-254.
    View in: PubMed
    Score: 0.179
  30. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 01 15; 6(1):88-94.
    View in: PubMed
    Score: 0.161
  31. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114.
    View in: PubMed
    Score: 0.140
  32. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785.
    View in: PubMed
    Score: 0.137
  33. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8.
    View in: PubMed
    Score: 0.133
  34. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol. 2024 Nov; 49:100866.
    View in: PubMed
    Score: 0.062
  35. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
    View in: PubMed
    Score: 0.062
  36. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  37. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
    View in: PubMed
    Score: 0.057
  38. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu?rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 10; 6(5):531-534.
    View in: PubMed
    Score: 0.057
  39. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.053
  40. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.051
  41. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol. 2022 Mar; 207(3):551-558.
    View in: PubMed
    Score: 0.051
  42. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.
    View in: PubMed
    Score: 0.050
  43. Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu?rin induction does not impact therapeutic response. BJU Int. 2021 11; 128(5):634-641.
    View in: PubMed
    Score: 0.049
  44. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.047
  45. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec; 37(12):2691-2698.
    View in: PubMed
    Score: 0.042
  46. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 01; 75(1):8-10.
    View in: PubMed
    Score: 0.041
  47. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293.
    View in: PubMed
    Score: 0.041
  48. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.040
  49. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98.
    View in: PubMed
    Score: 0.040
  50. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250.
    View in: PubMed
    Score: 0.039
  51. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251.
    View in: PubMed
    Score: 0.038
  52. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.038
  53. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.038
  54. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724.
    View in: PubMed
    Score: 0.036
  55. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
    View in: PubMed
    Score: 0.029
  56. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.